About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Cancer Cachexia Pipeline Market Insights Report 2025 | Analysis of Over 15 Companies and 20 Pipeline Drugs - ResearchAndMarkets.com

The "Cancer Cachexia - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.

The report delivers in-depth analysis of over 15 companies and 20 pipeline drugs in the cancer cachexia landscape. It comprises both clinical and nonclinical stage product profiles. The document includes therapeutic assessments by product type, development stage, administration route, and molecule type. It also highlights inactive pipeline products in this area.

Cancer cachexia is a multifactorial syndrome causing progressive skeletal muscle mass loss, often paired with systemic inflammation and altered metabolism. It's prevalent in advanced-stage cancers like pancreatic, gastric, lung, and colorectal, significantly impacting patient morbidity and mortality. Characterized by an inflammatory response, altered metabolism, and reduced food intake, it leads to debilitating weight loss, muscle atrophy, and fatigue. Traditional nutritional support proves inadequate, necessitating complex treatment strategies targeting both tumor and host factors.

The report uncovers the disease's pathophysiology, which involves tumor-derived molecules and host inflammatory cytokines that disrupt metabolism and appetite regulation. Cancer cachexia progresses through stages: precachexia, cachexia, and refractory cachexia, each with distinct clinical criteria. Management is multidisciplinary, comprising nutritional, pharmacological, and rehabilitative interventions. While appetite stimulants, anti-inflammatory agents, and anabolic therapies are explored, no definitive cure exists, underscoring an urgent need for innovative approaches.

The report sheds light on the cancer cachexia pipeline, profiling therapeutic candidates like FDY-8801 by Faraday Pharmaceuticals and S-oxprenolol by Actimed Therapeutics in the Phase II development stage. Other emerging therapies include GFS202A by GenFleet Therapeutics, a Phase I trial bispecific antibody, and EXT418 from Extend Biosciences, an investigational preclinical candidate.

The document categorizes approximately 20+ products by development phases such as late-stage (Phase III), mid-stage (Phase II), early-stage (Phase I), and preclinical. It also assesses the route of administration, product molecule type, and inactive candidates. Additionally, the report highlights Cancer Cachexia therapeutic advancements, collaborations, licensing activities, and acquisitions.

Insights include the pipeline analysis, unmet needs, drug impact, and therapeutic assessment. The report outlines emerging technologies addressing existing treatment limitations, key collaborations, mergers, licensing activities, and clinical study statuses. It identifies leading companies such as Genfleet Therapeutics and Faraday Pharmaceuticals at the forefront of cancer cachexia drug development.

Among the pipeline assets, key products include GFS202A, EXT418, FDY-8801, and ACM-001.1, with potential impacts on progressing therapeutic interventions in cancer cachexia management.

Key Topics Covered:

Introduction

Executive Summary

Cancer Cachexia: Overview

  • Introduction
  • Signs and Symptoms
  • Risk Factors
  • Pathophysiology
  • Diagnosis
  • Treatment

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Cancer Cachexia - Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Mid Stage Products (Phase II)

  • Comparative Analysis

Early Stage Products (Phase I)

  • Comparative Analysis

Preclinical and Discovery Stage Products

  • Comparative Analysis

Inactive Products

  • Comparative Analysis

Cancer Cachexia Key Companies

Cancer Cachexia Key Products

Cancer Cachexia - Unmet Needs

Cancer Cachexia - Market Drivers and Barriers

Cancer Cachexia - Future Perspectives and Conclusion

Cancer Cachexia Analyst Views

Appendix

Companies Featured

  • Genfleet Therapeutics (Shanghai) Inc.
  • Extend Biosciences
  • Faraday Pharmaceuticals
  • Actimed Therapeutics
  • Pfizer
  • NGM Biopharmaceuticals
  • AVEO Pharmaceuticals Inc.

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/mput3k

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com



For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.